{
    "2019-03-27": [
        [
            {
                "time": "",
                "orginal_text": "深读复星：产业大生态和投资大风口",
                "features": {
                    "keywords": [
                        "复星",
                        "产业大生态",
                        "投资大风口"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "orginal_text": "【安信非银】复星国际年报点评：生态布局初显成效，投资聚焦注重科创",
                "features": {
                    "keywords": [
                        "复星国际",
                        "生态布局",
                        "投资聚焦",
                        "科创"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "复星国际去年营收首破千亿元 郭广昌：投资将以控股型为主",
                "features": {
                    "keywords": [
                        "复星国际",
                        "营收",
                        "控股型投资"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "【国信医药|年报点评】复星医药（600196.SH）：利润触底回升，生物药扬帆起航",
                "features": {
                    "keywords": [
                        "复星医药",
                        "利润触底回升",
                        "生物药"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "医疗保健：科技创新将成为主旋律 荐6股",
                "features": {
                    "keywords": [
                        "医疗保健",
                        "科技创新"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗保健"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "orginal_text": "2019中国创新药全球化布局 信达等企业取得突破性进展",
                "features": {
                    "keywords": [
                        "创新药",
                        "全球化布局",
                        "信达"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "orginal_text": "【国金研究】保险资金专题：险资如何配置A股及其相关特征",
                "features": {
                    "keywords": [
                        "保险资金",
                        "A股配置"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "保险"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "orginal_text": "复星医药净利润下滑 研发费用上升投资收益减少是主因？ 盈利能力下降",
                "features": {
                    "keywords": [
                        "复星医药",
                        "净利润下滑",
                        "研发费用",
                        "投资收益减少"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "orginal_text": "复星医药去年净利27.08亿同比减13% 董事长陈启宇年薪1425万元 盈利能力下降",
                "features": {
                    "keywords": [
                        "复星医药",
                        "净利下降",
                        "盈利能力下降"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "orginal_text": "2018年复星国际总收入首破千亿元，投资近半数是海外项目",
                "features": {
                    "keywords": [
                        "复星国际",
                        "总收入",
                        "海外项目"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "复星医药CEO吴以芳：复宏汉霖H股上市策略不变 正认真研究科创板",
                "features": {
                    "keywords": [
                        "复星医药",
                        "复宏汉霖",
                        "H股上市",
                        "科创板"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "orginal_text": "遇研发阵痛 复星医药四年来净利首次下滑 盈利能力下降",
                "features": {
                    "keywords": [
                        "复星医药",
                        "研发阵痛",
                        "净利下滑",
                        "盈利能力下降"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}